Cargando…

Association between Serum Soluble Urokinase-Type Plasminogen Activator Receptor Level and Arterial Stiffness in Chronic Hemodialysis Patients

Cardiovascular diseases (CVDs) remain a significant cause of death in hemodialysis (HD) patients. To explore their associations, we examine the role of soluble urokinase-type plasminogen activator receptor (suPAR) in arterial stiffness in chronic HD patients. From June to August 2020, we recruited 1...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lin, Wei-Chen, Wu, Tsung-Jui, Wang, Chih-Hsien, Hsieh, Yi-Jen, Hsu, Bang-Gee
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10051056/ https://www.ncbi.nlm.nih.gov/pubmed/36983652 http://dx.doi.org/10.3390/jpm13030470

Ejemplares similares

Soluble Urokinase-Type Plasminogen Activator Receptor and Arterial Stiffness in Patients with COPD
por: Böcskei, Renáta M., et al.
Publicado: (2019)

Clinical and prognostic usefulness of soluble urokinase plasminogen activator receptor in hemodialysis patients
por: Wlazeł, Rafał Nikodem, et al.
Publicado: (2018)

Serum P-Cresyl Sulfate Is a Predictor of Central Arterial Stiffness in Patients on Maintenance Hemodialysis
por: Lai, Yu-Hsien, et al.
Publicado: (2019)

Elevation of serum urokinase plasminogen activator receptor and liver stiffness in postoperative biliary atresia
por: Udomsinprasert, Wanvisa, et al.
Publicado: (2016)

High serum leptin levels are associated with central arterial stiffness in geriatric patients on hemodialysis
por: Kuo, Chiu-Huang, et al.
Publicado: (2018)

Hyperleptinemia positively associated with central arterial stiffness in hemodialysis patients
por: Kuo, Chiu-Huang, et al.
Publicado: (2018)

Evaluation of Urokinase Plasminogen Activator Receptor, Soluble Urokinase Plasminogen Activator Receptor, and β1 Integrin in Patients with Hodgkin's Lymphoma
por: Kouhpayeh, Shirin, et al.
Publicado: (2017)

Association between serum soluble urokinase-type plasminogen activator receptor and atrial fibrillation
por: Ichihara, Noboru, et al.
Publicado: (2017)

Serum soluble urokinase plasminogen activator receptor in adolescents: interaction of chronic pain and obesity
por: Raff, Hershel, et al.
Publicado: (2020)

Serum Malondialdehyde-Modified Low-Density Lipoprotein Is a Risk Factor for Central Arterial Stiffness in Maintenance Hemodialysis Patients
por: Hou, Jia-Sian, et al.
Publicado: (2020)

Soluble Urokinase Plasminogen Activator Receptor (suPAR) and All-Cause and Cardiovascular Mortality in Diverse Hemodialysis Patients
por: Torino, Claudia, et al.
Publicado: (2018)

Serum soluble urokinase plasminogen activator receptor (suPAR) in adults with growth hormone deficiency
por: Höybye, Charlotte, et al.
Publicado: (2019)

Acute and Long-Term Treatment With Dapagliflozin and Association With Serum Soluble Urokinase Plasminogen Activator Receptor
por: Rotbain Curovic, Viktor, et al.
Publicado: (2022)

Soluble Urokinase Plasminogen Activator Receptor as a Marker for Use of Antidepressants
por: Haastrup, Eva, et al.
Publicado: (2014)

Soluble urokinase plasminogen activator receptor predicts mortality in exacerbated COPD
por: Godtfredsen, Nina S., et al.
Publicado: (2018)

Soluble urokinase plasminogen activator receptor for the prediction of ventilator-associated pneumonia
por: van Oort, Pouline M., et al.
Publicado: (2019)

Kinetics of the soluble urokinase plasminogen activator receptor (suPAR) in cirrhosis
por: Garnæs, Emilie, et al.
Publicado: (2019)

Soluble urokinase plasminogen activator receptor level in individuals of advanced age
por: Wlazel, Rafal N., et al.
Publicado: (2020)

Soluble Urokinase Plasminogen Activator Receptor and Venous Thromboembolism in COVID‐19
por: Luo, Shengyuan, et al.
Publicado: (2022)

Soluble Urokinase Plasminogen Activator Receptor and the Risk of Coronary Artery Disease in Young Chinese Patients
por: Huang, Yuli, et al.
Publicado: (2017)

Soluble urokinase-type plasminogen activator receptor predicts peripheral artery disease severity and outcomes
por: Höbaus, Clemens, et al.
Publicado: (2021)

WITHDRAWN: Soluble urokinase plasminogen activator receptor and its complicated role in hemodialysis (HD) patients with Covid-19 infection
por: Griveas, Ioannis, et al.
Publicado: (2022)

Serum levels of soluble urokinase plasminogen activator receptor as a new inflammatory marker in adolescent obesity
por: Can, Ummugulsum, et al.
Publicado: (2017)

Plasma Soluble Urokinase Plasminogen Activator Receptor in Children with Urinary Tract Infection
por: Wittenhagen, Per, et al.
Publicado: (2011)

A reassessment of soluble urokinase-type plasminogen activator receptor in glomerular disease
por: Spinale, Joann M., et al.
Publicado: (2014)

The Prognostic Significance of Soluble Urokinase Plasminogen Activator Receptor in Acute Myeloid Leukemia
por: Erkut, Nergiz, et al.
Publicado: (2016)

Circulating Soluble Urokinase-Type Plasminogen Activator Receptor in Obstructive Sleep Apnoea
por: Bocskei, Renata Marietta, et al.
Publicado: (2020)

Soluble urokinase plasminogen activator receptor (suPAR) in the emergency department: An update
por: Velissaris, Dimitrios, et al.
Publicado: (2022)

Correlation between Serum 25-Hydroxyvitamin D Level and Peripheral Arterial Stiffness in Chronic Kidney Disease Stage 3–5 Patients
por: Lee, Chung-Jen, et al.
Publicado: (2022)

Serum Trimethylamine N-Oxide Level Is Positively Associated with Aortic Stiffness Measured by Carotid–Femoral Pulse Wave Velocity in Patients Undergoing Maintenance Hemodialysis
por: Huang, Po-Yu, et al.
Publicado: (2023)

Soluble Urokinase‐Type Plasminogen Activator Receptor: A Useful Biomarker for Coronary Artery Disease and Clinical Outcomes?
por: Harskamp, Ralf E., et al.
Publicado: (2014)

Prognostic value of soluble urokinase‐type plasminogen activator receptor in coronary artery disease: A meta‐analysis
por: Li, Yang, et al.
Publicado: (2022)

Clinical value of soluble urokinase type plasminogen activator receptors in chronic kidney disease
por: Ahmed, Reem M., et al.
Publicado: (2019)

Soluble Urokinase Plasminogen Activator Receptor as a Diagnostic and Prognostic Biomarker in Cardiac Disease
por: Velissaris, Dimitrios, et al.
Publicado: (2021)

Detection of soluble urokinase type plasminogen activator receptors in children with gingivitis and normal subjects
por: El‑Patal, Mohamed Abd‑Ellatif, et al.
Publicado: (2022)

Risk Factors Associated with Serum Levels of the Inflammatory Biomarker Soluble Urokinase Plasminogen Activator Receptor in a General Population
por: Haupt, Thomas H, et al.
Publicado: (2014)

Increased Serum Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) Levels in FSGS: A Meta-Analysis
por: Lee, Jiwon M., et al.
Publicado: (2019)

Serum soluble urokinase type plasminogen activated receptor and focal segmental glomerulosclerosis: a systematic review and meta-analysis
por: Shuai, Tiankui, et al.
Publicado: (2019)

Serum Levels of Soluble Urokinase Plasminogen Activator Receptor Predict Tumor Response and Outcome to Immune Checkpoint Inhibitor Therapy
por: Loosen, Sven H., et al.
Publicado: (2021)

Serum Trimethylamine N-Oxide Level Is Associated with Peripheral Arterial Stiffness in Advanced Non-Dialysis Chronic Kidney Disease Patients
por: Hsu, Bang-Gee, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_lu1074eahh1tc3tmps2f3okhai